Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Clin Ther ; 21(6): 1058-72, 1999 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-10440627

RESUMO

We assessed the cost-effectiveness of daily calcium supplementation for the prevention of primary osteoporotic hip fractures. The assessment was based on our meta-analysis of the published relative-risk estimates from 3 double-masked, placebo-controlled, clinical trials and our analysis of raw data from the National Health and Nutrition Examination Survey 1988-1994 on the daily intake of calcium supplements by adults in the United States. These data were then used to estimate the preventable proportion of hip fractures. The 1995 National Hospital Discharge Survey database provided the number and demographic characteristics of patients discharged with a primary diagnosis of hip fracture, as well as their discharge destination. The 1990 itemized costs of hip fractures, as estimated by the US Congress Office of Technology Assessment, were inflated to 1995 dollars using the medical care component of the Consumer Price Index. Using these inflated itemized costs, we then estimated the weighted average expenditures, reflecting both the types of services associated with specific hospital-discharge destinations and the demographic characteristics of discharged patients. The cost of supplements containing 1200 mg/d of elemental calcium for the mean duration (34 months) of the 3 clinical trials was calculated on the basis of 1998 unit-price and market-share data for 6 representative products. For 1995, the data indicate that 290,327 patients aged > or =50 years were discharged from US hospitals with a primary diagnosis of hip fracture, at our estimated direct cost of $5.6 billion. Based on the risk reductions seen in the 3 trials, we estimated that 134,764 hip fractures and $2.6 billion in direct medical costs could have been avoided if individuals aged > or =50 years consumed approximately 1200 mg/d of supplemental calcium. Additional savings could be expected, because this intervention is also associated with significant reductions in the risk for all nonvertebral fractures. Comparing the cost of calcium with the expected medical savings from hip fractures avoided, it is cost-effective to give 34 months of calcium supplementation to women aged > or =75 years in the United States. If, as the published studies suggest, shorter periods of supplementation result in an equivalent reduction in the risk of hip fractures, calcium supplementation becomes cost-effective for all adults aged > or =65 years in the United States. The data support encouraging older adults to increase their intake of dietary calcium and to consider taking a daily calcium supplement. Even small increases in the usage rate of supplementation are predicted to yield significant savings and to reduce the morbidity and mortality associated with hip fracture at an advanced age.


Assuntos
Cálcio/economia , Cálcio/uso terapêutico , Suplementos Nutricionais/economia , Fraturas do Quadril/economia , Fraturas do Quadril/prevenção & controle , Osteoporose/complicações , Idoso , Idoso de 80 Anos ou mais , Animais , Gatos , Análise Custo-Benefício , Feminino , Custos de Cuidados de Saúde , Humanos , Metanálise como Assunto , Pessoa de Meia-Idade , Osteoporose/patologia , Fatores de Risco
2.
Manag Care Interface ; 11(10): 95-9, 1998 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-10186011

RESUMO

Published scientific studies show that perinatal consumption of multivitamins containing folic acid and zinc can significantly reduce the risks of low birthweight, premature births, spina bifida, and cardiovascular birth defects. Daily intake of vitamin E supplements reduces the risk of coronary heart disease in older Americans. The authors believe that if all at-risk Americans took the recommended amounts of vitamin supplements, significant numbers of hospitalizations for these conditions could be avoided, and the managed care industry could save approximately $5.5 billion, using 1995 figures.


Assuntos
Redução de Custos/estatística & dados numéricos , Programas de Assistência Gerenciada/economia , Vitaminas/uso terapêutico , Doença das Coronárias/prevenção & controle , Análise Custo-Benefício , Feminino , Ácido Fólico/administração & dosagem , Cardiopatias Congênitas/prevenção & controle , Hospitalização/economia , Humanos , Recém-Nascido de Baixo Peso , Recém-Nascido , Avaliação de Resultados em Cuidados de Saúde , Gravidez , Resultado da Gravidez , Cuidado Pré-Natal/economia , Disrafismo Espinal/prevenção & controle , Estados Unidos , Vitaminas/economia , Zinco/administração & dosagem
3.
West J Med ; 166(5): 306-12, 1997 May.
Artigo em Inglês | MEDLINE | ID: mdl-9217432

RESUMO

This study used published relative risk estimates for birth defects, premature birth, and coronary heart disease associated with vitamin intake to project potential annual cost reductions in U.S. hospitalization charges. Epidemiological and intervention studies with relative risk estimates were identified via MEDLINE. Preventable fraction estimates were derived from data on the percentage of at-risk Americans with daily vitamin intake levels lower than those associated with disease risk reduction. Hospitalization rates were obtained from the 1992 National Hospital Discharge Survey. Charge data from the 1993 California Hospital Discharge Survey were adjusted to 1995 national charges using the medical component of the Consumer Price Index. Based on published risk reductions, annual hospital charges for birth defects, low-birth-weight premature births, and coronary heart disease could be reduced by about 40, 60, and 38%, respectively. For the conditions studied, nearly $20 billion in hospital charges were potentially avoidable with daily use of folic acid and zinc-containing multivitamins by all women of childbearing age and daily vitamin E supplementation by those over 50.


Assuntos
Redução de Custos , Alimentos Fortificados , Preços Hospitalares , Hospitalização/economia , Vitaminas/uso terapêutico , Adulto , Anormalidades Congênitas/economia , Anormalidades Congênitas/epidemiologia , Doença das Coronárias/economia , Doença das Coronárias/epidemiologia , Feminino , Ácido Fólico/uso terapêutico , Humanos , Recém-Nascido de Baixo Peso , Recém-Nascido , Pessoa de Meia-Idade , Medição de Risco
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA